Dry And Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three vascular endothelial growth factor (VEGF) inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. Roche’s Susvimo (ranibizumab port delivery system [PDS]), which launched in November 2021 in the United States, will also continue to attract a small patient share because of its less-frequent dosing regimen of once every six months. Additionally, we expect Roche / Chugai’s Vabysmo (faricimab), which launched in the United States in February 2022, in the United Kingdom and Japan in May 2022, and in Germany in October 2022, to continue to experience strong uptake, driven by its new mechanism of action (MOA) and advantageous dosing regimen. More therapies for wet AMD are in the late-phase pipeline, including Regeneron / Bayer’s high-dose aflibercept and biosimilar agents. In contrast to the management of wet AMD, the management of dry AMD is limited; no prescription therapies are approved for this large subpopulation. However, in March 2023, Apellis’s pegcetacoplan launched as Syfovre in the United States, the first therapy approved for geographic atrophy (GA), and in December 2022, Astellas and Iveric Bio submitted a new drug application (NDA) for the C5 complement inhibitor Zimura, which will undergo an FDA review in August 2023.

Questions answered

  • How will the wet AMD treatment algorithm change as new products launch?
  • To what extent will novel therapies such as Roche’s faricimab capitalize on the need for therapies with longer dosing intervals?
  • How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?
  • How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
  • What will be the impact of Outlook Therapeutics’ ONS-5010 on Avastin if it launches for wet AMD, particularly in the United States?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 25 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total prevalence of late AMD, by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2031, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase 3 / PR: 7 drugs; Phase 2: 12 drugs; coverage of select Phase 1 products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature updates in 2023 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Dry and Wet Age-Related Macular Degeneration - Key Findings - August 2023
    • Key Updates
      • August 2023
      • June 2023
      • May 2023
      • April 2023
      • January 2023
      • Q4 2022
        • December 2022
        • November 2022
    • Market Outlook
      • Key findings
        • Market share of drug classes for AMD: 2021
        • Market share of drug classes for AMD: 2031
        • Dry and wet AMD SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for AMD?
        • What factors are constraining the market for AMD?
        • Major-market sales and treated patients in AMD: 2021-2031
        • Major-market brand and biosimilar sales and market share for VEGF inhibitors in wet AMD: 2021-2031
        • Market share and share of treated patients for wet AMD by region: 2021-2031
      • Drug class-specific trends
        • Patient share of VEGF inhibitors in wet AMD in the United States: 2021-2031
        • Patient share of VEGF inhibitors in wet AMD in Europe: 2021-2031
        • Patient share of VEGF inhibitors in wet AMD in Japan: 2021-2031
        • Major-market sales of VEGF inhibitors in wet AMD: 2021-2031
        • Patient share of faricimab in wet AMD in the major markets: 2021-2031
        • Major-market sales of faricimab in wet AMD: 2021-2031
        • Sales of complement system inhibitors in GA in the United States: 2021-2031
        • Sales of complement system inhibitors in GA in Europe: 2021-2031
        • Patient share of complement system inhibitors in GA in Europe: 2021-2031
    • Forecast
      • Market forecast downloads
      • Market forecast assumptions u2013 dry and wet age-related macular degeneration (2021-2031) u2013 August 2023
      • Market forecast dashboard - dry and wet age-related macular degeneration (2021-2031) - August 2023
    • Etiology and Pathophysiology
      • Disease overview
        • Pathophysiology
          • Disease classifications
          • Anatomy of the eye
          • Pathology
        • Etiology
          • Mechanisms associated with AMD pathogenesis
        • Risk factors
          • Genetic risk factors
          • Genetic markers associated with AMD
          • Other risk factors
          • Demographic and environmental risk factors associated with AMD
        • Key pathways and drug targets
          • Potential drug targets for AMD
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition, methods, and sources used
            • Total prevalent cases of late AMD: 2021-2031 (thousands)
            • Disease definition, methods, and sources used
            • Total prevalent cases of GA and wet AMD: 2021-2031 (thousands)
            • Diagnosed prevalent cases of wet AMD: 2021-2031 (thousands)
            • Diagnosed prevalent cases of GA: 2021-2031 (thousands)
            • Drug-treated wet AMD cases: 2021-2031 (thousands)
            • Drug-treated GA cases: 2021-2031 (thousands)
        • Current Treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for AMD
              • Imaging techniques used in evaluating AMD
            • Key current therapies
              • Overview
              • Mechanism of action of key current drug classes used for AMD
              • Current treatments used for AMD
              • Commonly used treatment regimens for VEGF inhibitors in wet AMD in clinical practice
              • Market events impacting the use of key current therapies in AMD
              • Advantages and disadvantages of Lucentis
              • Expert insight on Lucentis
              • Advantages and disadvantages of Eylea
              • Expert insight on Eylea
              • Advantages and disadvantages of Avastin
              • Expert insight on Avastin
              • Advantages and disadvantages of Beovu
              • Ongoing clinical development of Beovu
              • Key ongoing clinical trials of Beovu in the treatment of wet AMD
              • Expert insight on Beovu
              • Susvimo
              • Advantages and disadvantages of Susvimo
              • Key results from select clinical trials investigating Susvimo for the treatment of wet AMD
              • Ongoing clinical development of Susvimo
              • Key ongoing clinical trials of Susvimo in the treatment of wet AMD
              • Expert insight on Susvimo
              • Vabysmo
              • Advantages and disadvantages of Vabysmo
              • Key results from select clinical trials investigating Vabysmo for the treatment of wet AMD
              • Ongoing clinical development of Vabysmo
              • Key ongoing clinical trials of Vabysmo in the treatment of wet AMD
              • Expert insight on Vabysmo
              • Advantages and disadvantages of Visudyne / photodynamic therapy
              • Syfovre
              • Advantages and disadvantages of Syfovre
              • Key results from select clinical trials investigating Syfovre for the treatment of GA
              • Ongoing clinical development of Syfovre
              • Key ongoing clinical trials of Syfovre in the treatment of GA
              • Expert insight: Syfovre
            • Medical practice
              • Overview
              • Factors influencing drug selection in wet AMD
              • Treatment decision tree for AMD: United States
              • Treatment decision tree for AMD: Europe
              • Treatment decision tree for AMD: Japan
          • Unmet Need Overview
            • Current and future attainment of unmet needs in AMD
            • Top unmet needs in AMD: current and future attainment
            • Expert insight: unmet need in AMD
          • Drug Pipeline
            • Pipeline
            • Regulatory Milestones
            • Indication Comparison
          • Emerging Therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for AMD
                • Estimated launch dates of key emerging therapies for the treatment of AMD
                • ONS-5010 profile
                • Analysis of the clinical development program for ONS-5010
                • Expert insight: ONS-5010
                • Expectations for launch and sales opportunity of ONS-5010 in wet AMD
                • High-dose aflibercept profile
                • Analysis of the clinical development program for high-dose aflibercept
                • Expert insight: high-dose aflibercept
                • Expectations for launch and sales opportunity of high-dose aflibercept in wet AMD
                • OPT-302 profile
                • Key ongoing clinical trials of OPT-302 in the treatment of wet AMD
                • Analysis of the clinical development program for OPT-302
                • Expert insight: OPT-302
                • Expectations for launch and sales opportunity of OPT-302 in wet AMD
                • Zimura profile
                • Analysis of the clinical development program for Zimura
                • Expert insight: Zimura
                • Expectations for launch and sales opportunity of Zimura in GA
                • RGX-314 profile
                • Key ongoing clinical trials of RGX-314 in the treatment of wet AMD
                • Analysis of the clinical development program for RGX-314
                • Expert insight: RGX-314
                • Expectations for launch and sales opportunity of RGX-314 in wet AMD
                • Risuteganib profile
                • Analysis of the clinical development program for risuteganib
                • Expectations for launch and sales opportunity of risuteganib in AMD
                • Select cell-based therapy profiles
                • Expert insight: cell-based therapies
                • ALK-001 profile
                • Analysis of the clinical development program for ALK-001
                • Expert insight: ALK-001
                • Expectations for launch and sales opportunity of ALK-001 in GA
              • Early-phase pipeline analysis
                • Select compounds in early-phase development for AMD
            • Access and Reimbursement Overview
              • Region-specific reimbursement practices
                • Key market access considerations in wet AMD: United States
                • General reimbursement environment: United States
                • Key market access considerations in wet AMD: EU5
                • General reimbursement environment: EU5
                • Key market access considerations in wet AMD: Japan
                • General reimbursement environment: Japan
            • Appendix
              • Abbreviations
              • Dry and wet AMD bibliography

          Login to access report